iclusig 15 mg
incyte biosciences distribution b.v. - olanda - ponatinibum - compr. film. - 15mg - inhibitori de protein-kinaza
iclusig 30 mg
incyte biosciences distribution b.v. - olanda - ponatinibum - compr. film. - 30mg - inhibitori de protein-kinaza
iclusig 45 mg
incyte biosciences distribution b.v. - olanda - ponatinibum - compr. film. - 45mg - inhibitori de protein-kinaza
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vezi secțiunile 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
glivec comprimate filmate 100 mg
novartis pharma ag - imatinibum - comprimate filmate - 100 mg
glivec comprimate filmate 400 mg
novartis pharma ag - imatinibum - comprimate filmate - 400 mg
latib 100 mg
adamed pharma s.a. - ungaria - imatinibum - caps. - 100mg - alte antineoplazice inhibitori de protein-kinaza
latib 400 mg
adamed pharma s.a. - ungaria - imatinibum - caps. - 400mg - alte antineoplazice inhibitori de protein-kinaza
imakrebin 100 mg
remedica ltd. - cipru - imatinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza
imakrebin 400 mg
remedica ltd. - cipru - imatinibum - compr. film. - 400mg - alte antineoplazice inhibitori de protein-kinaza